Bloomsbury Genetic Therapies ("Bloomsbury") is a biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. Launched in October 2022 with £5M in Seed funding from UCL Technology Fund, the Company is a spin-out of University College London and is underpinned by world-leading gene therapy and rare disease expertise from the Company’s academic founders, Professor Paul Gissen, Professor Manju Kurian, Professor Ahad Rahim and Professor Simon Waddington. Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.